NOVARTIS logo.jpg
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
May 27, 2022 18:58 ET | Novartis Pharma AG
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah...
AGC Biologics Longmont Cell and Gene Therapy Campus
AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
May 17, 2022 22:03 ET | AGC Biologics
SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector...
MRW.png
Cell and Gene Therapy Market Size, Growth, Trends [2022] | Global Industry Share, Key Players, Recent Developments, Type & Application, Challenges & Restraints, Revenue, Stakeholders and Forecast Research | Market Reports World
May 09, 2022 01:36 ET | Market Reports World
Pune, May 09, 2022 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy Market Size 2022 research report provides an in-depth analysis of market size, share, growth, trends, and forecast. The Cell and...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
March 25, 2022 08:03 ET | Novartis Pharma AG
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
Featured Image for Almac Group
Almac Pharma Services Expands Its Unique Ultra-Low Temperature Solutions for Advanced Therapy Medicinal Products
March 14, 2022 12:31 ET | Almac Group
CRAIGAVON, Northern Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial...
POMSnet Falcon MES Dashboard
POMSnet Falcon Dives Into Pharma and Biotech GMP Facilities Across the Globe
January 04, 2022 09:00 ET | POMS
HERNDON, Va., Jan. 04, 2022 (GLOBE NEWSWIRE) -- POMS Corporation releases POMSnet Falcon 2021.2 MES Dashboard and Analytics. POMSnet Falcon is perched to become the GMP facility standard for...
NOVARTIS logo.jpg
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
December 22, 2021 02:00 ET | Novartis Pharma AG
There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2 Acquisition will add GT005 to the Novartis portfolio,...
NOVARTIS logo.jpg
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
December 13, 2021 14:45 ET | Novartis Pharma AG
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation...
NOVARTIS logo.jpg
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
August 24, 2021 01:15 ET | Novartis Pharma AG
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12...
AGC Biologics Appoin
AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site
August 09, 2021 13:00 ET | AGC Biologics
LONGMONT, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment...